Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ENSC

ENSC - Ensysce Biosciences, Inc. Stock Price, Fair Value and News

$0.78-0.07 (-8.24%)
Market Closed

68/100

ENSC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

68/100

ENSC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.14

Target 3M

$0.92

Target 6M

$0.99

ENSC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ENSC Price Action

Last 7 days

-15.2%

Last 30 days

-22.8%

Last 90 days

-63.9%

Trailing 12 Months

-89.1%

ENSC RSI Chart

ENSC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ENSC Valuation

Market Cap

2.8M

Price/Earnings (Trailing)

-0.25

Price/Sales (Trailing)

0.62

EV/EBITDA

2.93

Price/Free Cashflow

-0.97

ENSC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.14

Target 3M

$0.92

Target 6M

$0.99

ENSC Fundamentals

ENSC Revenue

Revenue (TTM)

4.5M

Rev. Growth (Yr)

-85.58%

Rev. Growth (Qtr)

-64.04%

ENSC Earnings

Earnings (TTM)

-11.0M

Earnings Growth (Yr)

-663.51%

Earnings Growth (Qtr)

-115.12%

ENSC Profitability

EBT Margin

44.26%

Return on Equity

-911.83%

Return on Assets

-345.11%

Free Cashflow Yield

-102.87%

ENSC Investor Care

Shares Dilution (1Y)

171.37%

Diluted EPS (TTM)

-5.38

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20256.2M7.4M4.5M0
20241.7M1.4M4.4M5.2M
20232.7M3.0M3.1M2.2M
20223.9M3.6M2.7M2.5M
20213.8M3.7M3.6M3.5M
20200003.9M
Get all data in R, Python etc through our Historical Stock Data APIs

About Ensysce Biosciences, Inc.

ENSC
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative which releases clinically effective oxycodone; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse. The company is based in La Jolla, California.
 CEO
 WEBSITEensysce.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES7

Ensysce Biosciences, Inc. Frequently Asked Questions

ENSC is the stock ticker symbol of Ensysce Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Ensysce Biosciences, Inc. is 2.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ENSC's fair value in chart for subscribers.

The fair value guage provides a quick view whether ENSC is over valued or under valued. Whether Ensysce Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Ensysce Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ENSC.

As of Wed Jan 28 2026, ENSC's PE ratio (Price to Earnings) is -0.25 and Price to Sales (PS) ratio is 0.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ENSC PE ratio will change depending on the future growth rate expectations of investors.